Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib.
Philadelphia-chromosome (Ph)-positive acute myeloid leukemia (AML) is rare and prognosis is poor with a median survival of six to seven months only. We report on a patient with Ph-positive AML (FAB M2, major BCR/ABL1 mRNA transcript, b2a2), who is in sustained complete cytogenetic and molecular remission for 15 months. Cytarabine-based chemotherapy was discontinued after two courses due to infectious complications. Since the b2a2 transcript was still detectable, imatinib was started with quantitative RT-PCR monitoring. This result is promising and worth further evaluation to establish the role of imatinib in patients with Ph-positive AML.
Jentsch-Ullrich
Kathleen
K
University Hospital Magdeburg, Division of Hematology/Oncology, Leipziger Str.44, 39120 Magdeburg, Germany. Kathleen.Jentsch-Ullrich@Medizin.Uni-Magdeburg.de
Pelz
Antje-Friederike
AF
Braun
Holger
H
Koenigsmann
Michael
M
Mohren
Martin
M
Wieacker
Peter
P
Franke
Astrid
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D005260:Female; D015321:Gene Rearrangement; D016313:Genes, abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D051562:Proto-Oncogene Proteins c-bcr / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C496613:BCR protein, human; D051562:Proto-Oncogene Proteins c-bcr